2013
Contraception
Belkind U, Coupey S, Godfrey E, Kottke M, Patterson‐Rose S, Braverman P, Yen S, Isley M, Kaunitz A, Duffy K, Gold M. Contraception. 2013, 205-233. DOI: 10.1002/9781118538555.ch34.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsIntrauterine deviceContraceptive methodsSide effectsMechanism of actionUpper female genital tractYoung womenHormonal oral contraceptionPelvic inflammatory diseaseCommon side effectsOral contraceptive pillsLevonorgestrel intrauterine deviceBarrier contraceptive methodsRapid repeat pregnancyFirst-line contraceptionSystemic side effectsFemale genital tractPopular birth control methodBirth controlBirth control methodsContraceptive regimenLea's ShieldMethod initiationMenstrual abnormalitiesNext menstruationOral contraceptionPremenstrual Syndrome/Premenstrual Dysphoric Disorder and Mood Disorders
Dobbs M, Braverman P. Premenstrual Syndrome/Premenstrual Dysphoric Disorder and Mood Disorders. 2013, 281-284. DOI: 10.1002/9781118538555.ch42.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPremenstrual dysphoric disorderDysphoric disorderPremenstrual syndromeSevere PMS/PMDDPremenstrual syndrome/premenstrual dysphoric disorderSelective serotonin reuptake inhibitorsPMS/premenstrual dysphoric disorderNonpharmacologic treatment modalitiesSpecific presenting symptomsOnset of mensesOral contraceptive pillsSerotonin reuptake inhibitorsMenstrual-related symptomsPostmenarchal womenPresenting symptomPharmacologic treatmentBreast tendernessReuptake inhibitorsContraceptive pillsTreatment modalitiesMild casesLuteal phaseMood disordersPhysical symptomsAffective symptoms
2009
Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder
Breech L, Braverman P. Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder. International Journal Of Women's Health 2009, Volume 1: 85-95. PMID: 21072278, PMCID: PMC2971718, DOI: 10.2147/ijwh.s4338.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsOral contraceptive pillsPremenstrual dysphoric disorderPlacebo-controlled trialContraceptive pillsDysphoric disorderTherapeutic modalitiesLarge randomized placebo-controlled trialsLow-dose oral contraceptive pillDouble-blind placebo-controlled trialBlinded placebo-controlled trialNew oral contraceptive pillRandomized placebo-controlled trialTreatment of PMDDFluid retention symptomsOpen-label studyReproductive-age womenSignificant placebo effectMultiple therapeutic modalitiesBetter patient compliancePromising therapeutic modalityNovel progestinRetention symptomsBlood pressureSerum potassiumThrombotic events
1993
Contraception
Braverman P, Strasburger V. Contraception. Clinical Pediatrics 1993, 32: 725-734. PMID: 8275606, DOI: 10.1177/000992289303201204.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements